TRAb at Diagnosis and Drug Cessation Predicts Long-Term Relapse Risk after Antithyroid Drug Therapy for Graves' Thyrotoxicosis
Clinical Thyroidology® · 01.07.2026 · 38 (7) · 244-247
DOI: 10.1177/23299711261466445 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Thyroidology®, online erschienen am 13.07.2026. Verfasst von Sarah C. Brennan und 2 weiteren Autor:innen. Die Arbeit nennt 8 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Brennan, S. C., Tsang, V. H., & Gild, M. L. (2026). TRAb at Diagnosis and Drug Cessation Predicts Long-Term Relapse Risk after Antithyroid Drug Therapy for Graves' Thyrotoxicosis. Clinical Thyroidology®, 38(7), 244-247. https://doi.org/10.1177/23299711261466445
Vancouver
Brennan SC, Tsang VH, Gild ML. TRAb at Diagnosis and Drug Cessation Predicts Long-Term Relapse Risk after Antithyroid Drug Therapy for Graves' Thyrotoxicosis. Clinical Thyroidology®. 2026;38(7):244-247. doi:10.1177/23299711261466445
BibTeX
@article{Brennan2026,
author = {Brennan, Sarah C. and Tsang, Venessa H. and Gild, Matti L.},
title = {TRAb at Diagnosis and Drug Cessation Predicts Long-Term Relapse Risk after Antithyroid Drug Therapy for Graves' Thyrotoxicosis},
journal = {Clinical Thyroidology®},
year = {2026},
volume = {38},
number = {7},
pages = {244--247},
doi = {10.1177/23299711261466445}
}
EUVIMED